Pembrolizumab - Merck & Co

Drug Profile

Pembrolizumab - Merck & Co

Alternative Names: Anti-PD-1 monoclonal antibody - Merck; Humanised monoclonal IgG4 antibody against PD-1 - Merck; Keytruda; Lambrolizumab; MK-3475; SCH-900475

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co; The Leukemia & Lymphoma Society
  • Developer Aduro BioTech; Amgen; Augusta University; BerGenBio; Big Ten Cancer Research Consortium; BioLineRx; Canadian Cancer Trials Group; Dana-Farber Cancer Institute; DNAtrix; Eisai Co Ltd; Eli Lilly; Emory University; Exelixis; Fox Chase Cancer Center; Genexine; Gilead Sciences; Hoosier Cancer Research Network; Icahn School of Medicine at Mount Sinai; ImmunoGen; Incyte Corporation; Institute of Cancer Research; M. D. Anderson Cancer Center; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (France); National Cancer Institute (USA); Northwestern University; NYU Langone Medical Center; Oslo University Hospital; Plexxikon; Providence Health & Services; Sarcoma Alliance for Research through Collaboration; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Spanish Breast Cancer Research Group; TG Therapeutics Inc; University Health Network; University of Alabama; University of Birmingham; University of California at San Francisco; University of California, San Diego; University of Pittsburgh; Verastem; Washington University School of Medicine; Yale University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors; Programmed cell death 1 ligand 2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Urogenital cancer
  • Registered Gastric cancer
  • Phase III Breast cancer; Gastrointestinal cancer; Hepatocellular carcinoma; Liver cancer; Multiple myeloma; Oesophageal cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase II Adenocarcinoma; Bladder cancer; Bone cancer; Brain metastases; Cholangiocarcinoma; Diffuse large B cell lymphoma; Endometrial cancer; Fallopian tube cancer; Follicular lymphoma; Germ cell and embryonal neoplasms; Glioblastoma; Glioma; Inflammatory breast cancer; Lymphoma; Merkel cell carcinoma; Mesothelioma; Nasopharyngeal cancer; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Osteosarcoma; Ovarian cancer; Penile cancer; Peritoneal cancer; Prostate cancer; Rectal cancer; Recurrent respiratory papillomatosis; Sarcoma; Soft tissue sarcoma; Squamous cell cancer; Thymoma; Thyroid cancer
  • Phase I/II Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Phase I Haematological malignancies
  • Preclinical Human papillomavirus infections

Most Recent Events

  • 10 Oct 2017 Merck plans a phase III trial of pembrolizumab in combination with ipilimumab for Non-small cell lung cancer (Combination therapy, First-line therapy, Metastatic) in USA, Argentina, Brazil, Canada, Chile, Colombia, France, Germany, Hungary, Italy, South Korea, Latvia, Mexico, Peru, Poland, Russia, South Africa, Spain, Taiwan, Thailand, Turkey and Ukraine in November 2017 (NCT03302234)
  • 01 Oct 2017 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom (IV) (NCT03184571)
  • 28 Sep 2017 Phase-III clinical trials in Gastrointestinal cancer (Combination therapy, First-line therapy, Adjuvant therapy, Neoadjuvant therapy) in Germany, Singapore (IV) (NCT03221426)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top